QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 zimvie-stockholders-approve-acquisition-by-archimed-affiliate-merger-expected-to-close-on-october-20

ZimVie Inc. ("ZimVie") (NASDAQ:ZIMV) today announced that at the special meeting of ZimVie stockholders held on October...

 zimvie-announces-a-strategic-distribution-agreement-with-osstem-implant-co-to-further-expand-its-presence-into-the-large-growing-chinese-implant-market

PALM BEACH GARDENS, Fla., July 23, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the den...

 barclays-upgrades-zimvie-to-equal-weight-raises-price-target-to-19

Barclays analyst Matt Miksic upgrades ZimVie (NASDAQ:ZIMV) from Underweight to Equal-Weight and raises the price target from...

 archimed-affiliate-to-acquire-zimvie-for-730m-offering-99-premium-over-90-day-vwap

ZimVie Inc. ("ZimVie") (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced their...

 zimvie-launches-realguide-software-suite-and-implant-concierge-service-in-japan

ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced the launch of its RealGU...

 ubs-maintains-neutral-on-zimvie-lowers-price-target-to-10

UBS analyst Kevin Caliendo maintains ZimVie (NASDAQ:ZIMV) with a Neutral and lowers the price target from $16 to $10.

 zimvie-affirms-fy2025-adj-eps-guidance-of-080-095-vs-084-est-affirms-fy2025-sales-guidance-of-44500m-46000m-vs-45035m-est

ZimVie (NASDAQ:ZIMV) affirms FY2025 Adj EPS guidance from $0.80-$0.95 to $0.80-$0.95 vs $0.84 analyst estimate. Affirms FY2025 ...

 zimvie-q1-adj-eps-027-beats-021-estimate-sales-11200m-miss-11341m-estimate

ZimVie (NASDAQ:ZIMV) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.21 by 28.57...

 needham-reiterates-hold-on-zimvieto-hold

Needham analyst David Saxon reiterates ZimVie (NASDAQ:ZIMV) from Hold to Hold.

 dental-players-dentsply-sirona-zimvie-show-weak-growth-outlook-analyst

Needham downgraded Dentsply Sirona and ZimVie, citing weak growth, market share losses, and demand challenges amid high interes...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION